ROS1
11 drugs Oncology
5
approved indications
11
Approved Drugs
11
Companies
12
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (11 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (12 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EXELIXIS INC 1 drug
PF PRISM CV 1 drug
Roche 1 drug
By Therapeutic Area
Oncology 7 drugs
Other 4 drugs
By Therapeutic Area
Oncology 7 drugs
XALKORI, AUGTYRO, ALUNBRIG, ZYKADIA +3 more
Other 4 drugs
CABOMETYX, ROZLYTREK, COMETRIQ, RESNIBEN
Indications Treated
ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adultsNTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 monthNon-Small Cell Lung CancerMedullary Thyroid CancerAdvanced renal cell carcinomaHepatocellular carcinoma previously treated with sorafenibLocally advanced or metastatic differentiated thyroid cancerWell-differentiated pancreatic neuroendocrine tumorsWell-differentiated extra-pancreatic neuroendocrine tumorsAnaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorSolid Tumors
All Drugs Targeting ROS1
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| CABOMETYX | EXELIXIS INC | 2016 | 5 | |
| XALKORI | PF PRISM CV | 2011 | 3 | Oncology |
| ROZLYTREK | Roche | 2019 | 2 | |
| AUGTYRO | Bristol-Myers Squibb | 2023 | 2 | Oncology |
| ALUNBRIG | Takeda | 2017 | 1 | Oncology |
| ZYKADIA | Novartis | 2014 | 1 | Oncology |
| COMETRIQ | EXELIXIS | 2012 | 1 | |
| RESNIBEN | AZURITY | - | 1 | |
| IBTROZI | NUVATION | 2025 | 1 | Oncology |
| LORBRENA | Pfizer | 2018 | 1 | Oncology |
| ENSACOVE | XCOVERY | 2024 | 1 | Oncology |